Table 3.

Disease Characteristics and Outcomes in Complete Responders

CR/CRi Patient	Lineage	Baseline BM Blast (%)	Baseline PB Blast (%)	Relapse Status	Pre-VSLI HCT	Refractory to	VSLI Line of Therapy	VSLI Cumulative Exposure (mg)	VSLI Response (per PI)	Post-VSLI MRD	Post-VSLI HCT	CR/CRi Duration (days)	OS (days)	Post-VSLI Grade 3/4 Peripheral Neuropathy
1	B	99	96	2nd	+		3rd	15.8	CRi	+	+	132	327	None
2	T	25	51	2nd	+	Cytarabine and methotrexate	5th	20.6	CR	+	−	35	139	+ (3)
3	B	90	95	2nd	+		4th	19.6	CRi	+	−	42	71	None
4	B	95	94	2nd	−		3rd	27.2	CR	−	−	162	321	None
5	B	98	95	3rd	+		5th	17.4	CRi*	−	−	89	137	None
6	B	40	1	2nd	+		4th	43.2	CR	−	−	166	230	+ (4)
7	T	84	84	1st	+		3rd	33.4	CRi	+	+	210	267	+ (3)
8	B	75	40	1st	+		3rd	41.4	CR	−	+	162	230	None
9	B	93	93	2nd	−		3rd	30.3	CR	−	+	135	163	None
10	B	90	41	2nd	−	Clofarabine	4th	49.3	CRi	−	−	32	232	+ (3)
11	B	63	63	2nd	+		4th	58.6	CR	−	−	144	229	None
12	B	81	81	2nd	−	Vinorelbine, mitoxantrone, and cytarabine	4th	25.2	CR	N/A	+	463	699	None
13	B	30	54	1st	−	Clofarabine	3rd	26.1	CRi*	−	−	33	121	+ (3)

NOTE. Details regarding the drugs used in prior lines of therapy are available in Appendix Table A2 (online only).

Abbreviations: B, B cell; BM, bone marrow; CR, complete response; CRi, CR with incomplete hematologic recovery; HCT, hematopoietic cell transplantation; IRRC, independent response review committee; MRD, minimal residual disease; N/A, not applicable; OS, overall survival; PB, peripheral blood; PI, principal investigator; T, T cell; VSLI, vincristine sulfate liposome injection; +, affirmative; −, negative.

^*BMB per the IRRC.